Stefanelli Guglielmo, Pirro Fabrizio, Meli Marco, Trevisan Davide, Telesca Mariassunta, Campisano Barbara, Mussini Cristina, Barbieri Andrea
Department of Cardiac Surgery, Cardiology and Anesthesiology Hesperia Hospital, Modena, Italy
Department of Cardiac Surgery, Cardiology and Anesthesiology Hesperia Hospital, Modena, Italy.
Interact Cardiovasc Thorac Surg. 2016 Oct;23(4):593-8. doi: 10.1093/icvts/ivw176. Epub 2016 Jun 2.
The aim of this study is to evaluate the ease of use and the advantages of Sorin Pericarbon Freedom (SPF) stentless valve in cases of acute bacterial endocarditis and to check the intermediate-term results after the implant of SPF with respect to resistance to infection, valve deterioration and durability.
Between June 2003 and February 2015, 26 patients with active aortic valve bacterial endocarditis underwent aortic valve replacement with SPF pericardial stentless aortic prosthesis. The mean age was 57 ± 18 years; 73% of the patients were in preoperative NYHA class III and VI. Mean Logistic EuroSCORE was 14.2 ± 12.7. Endocarditis occurred in 18 patients with native valves, and in 9 patients with prosthetic valves (4 mechanical aortic valve prostheses; 5 aortic bioprostheses). Aortic root abscesses were observed in 16 cases (61.5%). Surgery was emergent in 3 cases (11.5%). Redo surgery was performed in 9 cases (35%). Cumulative follow-up was 126.8 patient-years (mean 4.9 ± 3.3 years).
Operative hospital mortality was 0% for all patients. Residual mean prosthetic gradient at discharge was 9.4 ± 3.6 mmHg. Neither residual aortic incompetence nor residual abscess cavity was observed at discharge. Mean ejection fraction at discharge was 54 ± 8% (Min; Max: 35%; 65%). A total of 4 patients died at follow-up, all for non-cardiac causes. One patient was lost to follow-up. Two patients (8%) underwent non-valve-related reoperation with 0% mortality. Residual mean gradient at follow-up was 7.2 ± 2.1 mmHg. Three patients (17%) presented with mild/moderate aortic incompetence and 89% of patients were in NYHA Class I-II at follow-up. At 9 years, actuarial freedom from valve-related reoperation and from structural valve deterioration was 100%.
The SPF aortic prosthesis is a true pericardial stentless prosthesis suitable for the treatment of acute bacterial endocarditis. Intermediate-time results in terms of freedom from reoperation, structural valve deterioration and resistance to infections are satisfactory. Haemodynamic performances are excellent since a complete exclusion of aortic root abscesses is achieved without any reduction of the aortic annular diameter, usually due to marsupialization or patch closure of the infected cavities.
本研究旨在评估索林Pericarbon Freedom(SPF)无支架瓣膜在急性细菌性心内膜炎病例中的易用性和优势,并检查植入SPF后的中期结果,包括抗感染能力、瓣膜退变情况和耐用性。
2003年6月至2015年2月期间,26例活动性主动脉瓣细菌性心内膜炎患者接受了SPF心包无支架主动脉瓣膜置换术。平均年龄为57±18岁;73%的患者术前纽约心脏协会(NYHA)心功能分级为III级和IV级。平均欧洲心脏手术风险评估系统(Logistic EuroSCORE)评分为14.2±12.7。18例患者为原发性瓣膜心内膜炎,9例为人工瓣膜心内膜炎(4例机械主动脉瓣假体;5例主动脉生物假体)。16例(61.5%)观察到主动脉根部脓肿。3例(11.5%)为急诊手术。9例(35%)进行了再次手术。累计随访时间为126.8患者年(平均4.9±3.3年)。
所有患者的手术住院死亡率为0%。出院时残余人工瓣膜平均压差为9.4±3.6 mmHg。出院时未观察到残余主动脉瓣关闭不全或残余脓肿腔。出院时平均射血分数为54±8%(最小值;最大值:35%;65%)。随访期间共有4例患者死亡,均为非心脏原因。1例患者失访。2例患者(8%)接受了非瓣膜相关再次手术,死亡率为0%。随访时残余平均压差为7.2±2.1 mmHg。3例患者(17%)出现轻度/中度主动脉瓣关闭不全,89%的患者随访时NYHA心功能分级为I-II级。9年时,瓣膜相关再次手术和结构性瓣膜退变的预期免发生率为100%。
SPF主动脉瓣膜假体是一种真正的心包无支架假体,适用于治疗急性细菌性心内膜炎。在再次手术、结构性瓣膜退变和抗感染方面的中期结果令人满意。血流动力学性能优异,因为通过对感染腔进行袋形缝合或补片闭合,在不减小主动脉环直径的情况下完全排除了主动脉根部脓肿。